MyOme announced an Illumina strategic investment and a planned prospective clinical trial — MyOme’s Proactive Health — combining clinical whole‑genome sequencing with AI risk models to evaluate outcomes and health‑economic impact. CEO Premal Shah said the firm aims to show improved early detection and triage could generate substantial healthcare savings while improving patient outcomes. Illumina framed the deal as part of its multiomics push, offering sequencing access and commercial collaboration. Company executives said the trial protocol is being finalized and enrollment is expected to start next year; observers noted payers and regulators will scrutinize evidence for clinical utility and cost claims.